At Integra Therapeutics we have combined the precision of CRISPR systems with the gene transfer efficiency of viral integrases and transposases. Harnessing what nature has evolved to introduce large pieces of DNA into the genome, together with the precision of sequence specific DNA binding proteins, has allowed for unprecedented efficiency in programmable gene delivery.
Location: Spain
Employees: 1-10
Total raised: $25.7M
Investors 1
| Date | Name | Website |
| 06.02.2022 | Takeda Ven... | takeda.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 08.09.2025 | Seed | $12.51M | European I... |
| 17.07.2024 | - | $11.49M | - |
| 30.03.2022 | Seed | $1.7M | Columbus V... |
Mentions in press and media 13
| Date | Title | Description |
| 08.09.2025 | Integra Therapeutics raises €10.7M to advance FiCAT platform and CAR-T validation | Barcelona-based Integra Therapeutics has closed a €10.7 million pre-Series A round to advance its gene writing technologies designed to improve the safety, precision, and efficacy of advanced therapies. Founded in 2020 by Dr. Marc Güell and... |
| 08.09.2025 | Integra Therapeutics Raises €10.7M in Funding | Integra Therapeutics, a Barcelona, Spain-based gene writing tools provider, raised €10.7M in funding. Backers included IC Fund (European Commission) and CDTI Innvierte (Government of Spain) and current investors (AdBio, Columbus, Invivo and... |
| 17.07.2024 | Integra Therapeutics to Receive Up To €10.5M from European Commission | Integra Therapeutics, a Barcelona, Spain-based company which specializes in gene writing tools, received up to €10.5M from European Commission via the European Innovation Council (EIC) Accelerator program The company intends to use the fund... |
| 17.07.2024 | Integra Therapeutics receives EIC Accelerator funds of up to €10.5M for gene writing tools | Biotech Integra Therapeutics, creator of gene writing tools to make advanced therapies safer and more effective, has been awarded up to €10.5 million from the EU via the European Innovation Council (EIC) Accelerator. The EIC Accelerator is ... |
| 30.03.2022 | Integra Therapeutics Raises €1.5M in Seed Funding From Columbus Venture Partners | Integra Therapeutics, a Barcelona, Spain-based biotechnology company that creates next- generation gene writing tools, raised an additional €1.5m in seed funding. Columbus Venture Partners (Columbus Life Science Fund III FCR) made the inves... |
| 30.03.2022 | Integra Therapeutics closes a new investment of €1.5-million with the addition of Columbus Venture Partners to seed round | Integra Therapeutics, a biotechnology company that creates next- generation gene writing tools, has closed an additional €1.5-million investment from venture capital firm Columbus Venture Partners. This investment comes on top of the €4.5 m... |
| 29.03.2022 | Integra Therapeutics cierra una ronda de €1,5M a la que acude Columbus Venture Partners | 29/03/2022 Nota de prensa INTEGRA THERAPEUTICS CIERRA UNA NUEVA INVERSIÓN DE €1,5 MILLONES CON LA INCORPORACIÓN DE COLUMBUS VENTURE PARTNERS EN LA RONDA SEED. La biotecnológica completa así su ronda seed con un total de 6 millones de euro... |
| 29.03.2022 | Integra Therapeutics closes a new investment of €1.5M with the addition of Columbus Venture Partners to seed round | 29/03/2022 Press release INTEGRA THERAPEUTICS CLOSES A NEW INVESTMENT OF €1,5 MILLION WITH THE ADDITION OF COLUMBUS VENTURE PARTNERS TO SEED ROUND. The biotechnology firm completes the seed round funding with a total of €6 million led las... |
| 02.12.2021 | Integra Tx cierra una ronda de €4,5M a la que han acudido Advent France Biotechnology, Invivo Capital y Takeda Ventures | 02/12/2021 Nota de prensa INTEGRA TX CIERRA UNA RONDA DE €4,5M CON ADVENT FRANCE BIOTECHNOLOGY, INVIVO CAPITAL Y TAKEDA VENTURES. La biotecnológica, especializada en edición genética y fundada por los investigadores Marc Güell y Avencia ... |
| 02.12.2021 | Integra Tx secures €4.5M in funding from Advent France Biotechnology, Invivo Capital and Takeda Ventures | 02/12/2021 Press release INTEGRA TX SECURES €4.5 MILLION IN FUNDING FROM ADVENT FRANCE BIOTECHNOLOGY, INVIVO CAPITAL AND TAKEDA VENTURES. The biotechnology company, which specialises in gene editing and was founded by researchers Marc Gü... |
Show more